DOCSLIB.ORG

Patient Outcome Medicines Safety Indicators (Pomsis)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patient Outcome Medicines Safety Indicators (Pomsis) Appendix 3 – Care Home Enhanced Service April 2018 Patient Outcome Medicines Safety Indicators (POMSIs) There are well documented common medication related causes for harm and/or admission to hospital. Studies have estimated at least 5% of hospital admissions are medicines related with around half potentially preventable. Four classes of medicines have been identified with around half of preventable admissions – antiplatelets (including aspirin), anticoagulants, NSAIDs and diuretics. There are also identified risk factors such as older age, co-morbidity, dependent living situation and polypharmacy which increase the risk of a medicines related admission. Within this Care Home enhanced service five key areas relating to 10 indicators have been identified. The aim is to try and reduce the potential for medication related harm within the care home setting by identifying the residents who are at risk from receiving these medicines and encourage multi professional discussion with the GP, practice pharmacist, nurse, carer, resident and/or family member to reduce the number of residents at recognised risk. The five key areas are - 1. Bleeds 2. Falls 3. Renal function 4. Infection 5. Confusion Bleeds Drug-induced bleeding is commonly thought of as gastrointestinal (GI) bleeding resulting from the use of non steroidal anti-inflammatory drugs (NSAIDs). Nosebleeds and abnormal bruising, in addition to GI bleeding, may be linked to the use of oral anticoagulants. Falls Between 230,000 and 460,000 people over the age of 60 fall in Wales each year. Falls are one of the leading causes of admission to hospital, with around 21,000 fall related in-patient admissions each year, which result in length of stays which are twice as long as the average. On an individual level falls have a profoundly negative impact on a person’s life leading to reduced confidence and independence. Falls are not an inevitable part of ageing; there are many factors which can contribute to a fall, with medication, poor eyesight and lack of exercise being amongst the key risks. Studies have identified nine major classes of medication which have a significant association with falls - neuroleptics, antipsychotics, antihypertensives, diuretics, beta-blockers, sedatives and hypnotics, benzodiazepines, non-steroidal anti-inflammatory drugs or narcotics. Stopping, reducing or monitoring (such as lying and standing blood pressure) these medicines will reduce an individuals risk of falling. Appendix 3 – Care Home Enhanced Service April 2018 Renal Function (Acute Kidney Injury (AKI)) Acute kidney injury (AKI) is the sudden loss of kidney function over a period of hours or days. Since the kidneys are one of the major excretory pathways for the removal of drugs from the body, this sudden loss of kidney function can have major implications for a patient’s prescribed medication regime. Renal function declines with age; many elderly patients have renal impairment but because of reduced muscle mass, this may not be indicated by a raised serum creatinine. Many drugs can be harmful to the kidneys especially in people with AKI or at risk of it for non-pharmacological reasons. In addition, other drugs – such as those with a narrow therapeutic range and those that are cleared by the kidneys – may cause toxicity in the setting of AKI and acute illness, requiring additional monitoring, dose adjustment and measurement of drug levels Clostridium difficile infection There are growing concerns about long term treatment with Proton Pump Inhibitor (PPI) therapy and association with, amongst others, Clostridium difficile infection and increased risk of bone fractures in susceptible populations. PPIs have recognised benefits in certain GI conditions but gastric acid suppression has been a suggested risk factor for Clostridium difficile infection. Confusion Behavioural and psychological symptoms (BPSD), such as restlessness and shouting, are very commonly experienced at points in time in people with dementia. Antipsychotic medications are frequently prescribed first line to treat BPSD though it has been estimated that around two thirds of these prescriptions are inappropriate and the symptoms can be managed without medication. Evidence appears to show that the benefits of antipsychotic use is limited over longer periods. Antipsychotics are associated with an increased risk of falls, delirium, cerebrovascular events and all-cause death. Anticholinergic medication can produce adverse effects such as constipation, urinary retention, dry mouth/eyes, sedation, confusion, delirium, photophobia, falls and reduced cognition (may lead to wrong diagnosis of dementia). There is also a suggested link between increased mortality and the number and potency of anticholinergic agents prescribed. Elderly patients are more likely to experience these adverse effects so should be used cautiously with increasing age. The Anticholinergic Risk Scale is useful to raise awareness of anticholinergic effects of different medicines. A number of studies have been published which aim to assign drugs with one, two or three points; the higher the number, the stronger the anticholinergic effect. Appendix 3 – Care Home Enhanced Service April 2018 1 Point 2 Points 3 Points Amiodarone Amantadine Alimemazine (trimeprazine) Aripiprazole Chlorphenamine Amitriptyline Bromocriptine Desipramine Atropine Carbamazepine Dicycloverine Benztropine Citalopram (dicyclomine) Chlorpromazine Diazepam Dimenhydrinate Clemastine Domperidone Diphenhydramine Clomipramine Fentanyl Disopyramide Clozapine Fluoxetine Levomepromazine Cyproheptadine Fluphenazine Olanzapine Dothiepin (dosulepin) Hydroxyzine Paroxetine Doxepin Iloperidone Pethidine Hyoscine hydrobromide Lithium Pimozide Imipramine Mirtazepine Prochlorperazine Lofepramine Perphenazine Promazine Nortriptyline Prednisolone Propantheline Orphenadrine Quinidine Quetiapine Oxybutynin Sertindole Tolterodine Procyclidine Sertraline Trifluoperazine Promethazine Solifenacin Trihexyphenidryl (benzhexol) Temazepam Trimipramine http://www.awmsg.org/docs/awmsg/medman/National%20Prescribing%20Indicators%202017-2018.pdf Ten indicators for audit Drug/Class Referral/review Include (generic and brands) criteria 1 Proton Pump At high or treatment Pantoprazole 40mg Inhibitor dose for over 8 weeks Lansoprazole 30mg Omeprazole 40mg Esomeprazole 40mg Rabeprazole 20mg 2 Hypnotics and Long term (over 4 All oral benzodiazepines and Benzodiazepines weeks) “Z-drugs”. 3 Antipsychotics Currently prescribed All oral antipsychotics. 4 Antipsychotics With dementia All oral antipsychotics 5 NSAIDs and/or Long term (over 3 All oral non-steroidal anti- COX II months) inflammatories. 6 NSAIDs and/or Without PPI/H2RA All oral non-steroidal anti- COX II inflammatories. 7 Bisphosphonates Unable to take dose All oral bisphosphonates. correctly - stay fully upright for at least 30 minutes or one hour after taking the tablet 8 Anticholinergic Aged 75 and over, and All medicines listed in Burden currently prescribed – anticholinergic effects table Appendix 3 – Care Home Enhanced Service April 2018 with cumulative score below. of 3 or over 9 Antihypertensives Does not have a blood All regular antihypertensives pressure recorded in (as per BNF listing) last 6 months 10 Warfarin, Does not have an up to All patients receiving warfarin, Methotrexate, date monitoring booklet methotrexate or lithium Lithium Method The contracted pharmacy is required to identify the number of residents in each home who meet the above indicators. This may involve liaising with the home to seek further individual resident information. For all indicators the number of residents currently in the home and the number meeting each indicator should be recorded on NECAF. A list of residents meeting each indicator should also be produced for each home/GP and discussed with the residents GP and/or practice pharmacist (unless otherwise advised by Health Board), in addition to understanding the reasoning behind the risks and a suggested action plan for the residents. This process will be repeated and reported every six months. Outcomes The number of residents meeting each indicator will be reviewed at a Health Board and national level with an expectation of a reduction within these identified risk areas which evidence suggests will improve outcomes for the individual residents. References and suggested reading AWMSG Polypharmacy Guidance for Prescribing - http://www.awmsg.org/docs/awmsg/medman/Polypharmacy%20- %20Guidance%20for%20Prescribing.pdf WeMeReC - www.wemerec.org/Documents/enotes/StoppingPPIsenotes.pdf WeMeReC - www.wemerec.org/Documents/enotes/WithdrawingBenzodiazepine2009.pdf AWMSG Towards appropriate NSAID prescribing - http://www.awmsg.org/docs/awmsg/medman/All%20Wales%20Audit%20- %20Towards%20Appropriate%20NSAID%20Prescribing.pdf Bisphosphonates – https://www.gov.uk/government/publications/bisphosphonates-use-and- safety/bisphosphonates-use-and-safety Warfarin – http://www.nrls.npsa.nhs.uk/resources/?EntryId45=61777 Appendix 3 – Care Home Enhanced Service April 2018 Methotrexate - http://www.nrls.npsa.nhs.uk/resources/?entryid45=59800 Lithium - http://www.nrls.npsa.nhs.uk/alerts/?entryid45=65426 Renal (AKI) - https://www.thinkkidneys.nhs.uk/aki/wp- content/uploads/sites/2/2016/03/Guidelines-for-Medicines-optimisation-in-patients- with-AKI-final.pdf Meds related admission - https://www.wemerec.org/Documents/Bulletins/Medicines- related%20admissions-online.pdf .
Load more

Recommended publications
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Chlorphenamine Maleate)
    Package leaflet: Information for the patient Chlorphenamine 10 mg/ml Solution for Injection (Chlorphenamine Maleate) Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. − Keep this leaflet. You may need to read it again. − If you have any further questions, ask your doctor or nurse. − If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Chlorphenamine is and what it is used for 2. What you need to know before Chlorphenamine is given 3. How Chlorphenamine is given 4. Possible side effects 5. How to store Chlorphenamine 6. Contents of the pack and other information 1. What Chlorphenamine is and what it is used for Chlorphenamine 10 mg/ml Solution for Injection contains the active ingredient chlorphenamine maleate which is an antihistamine. Chlorphenamine is indicated in adults and children (aged 1 month to 18 years) for the treatment of acute allergic reactions. These medicines inhibit the release of histamine into the body that occurs during an allergic reaction. This product relieves some of the main symptoms of a severe allergic reaction. 2. What you need to know before Chlorphenamine is given You MUST NOT be given Chlorphenamine: if you are allergic to chlorphenamine maleate or any of the other ingredients of this medicine (listed in section 6) if you have had monoamine oxidase inhibitor (MAOI) antidepressive treatment within the past 14 days. Warnings and precautions Talk to your doctor or nurse before you are given this medicine if you: are being treated for an overactive thyroid or enlarged prostate gland have epilepsy, raised blood pressure within the eye or glaucoma, very high blood pressure, heart, liver, asthma or other chest diseases.
    [Show full text]
  • Prescribing Trends of Antihistamines in the Outpatient Setting in Al-Kharj
    Prescribing Trends of Antihistamines in the Outpatient Setting in Al-Kharj Nehad J. Ahmed1*, Menshawy A. Menshawy2 1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia, 2Department of Medicinal chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia Abstract Aim: This study aims to illustrate the prescribing trends of antihistamines in the outpatient setting in Al-Kharj. Materials and Methods: This is a retrospective study that included the evaluation of antihistamines in the outpatient setting in a public hospital in Al-Kharj. The data were collected from the pharmacy-based computer system. Results: The total number of prescriptions that included antihistamines was 799. Most of the prescribed ORIGINAL ARTICLE ARTICLE ORIGINAL antihistamines were first-generation sedating antihistamines (chlorphenamine and diphenhydramine) (66.33%). About 63.20% of the prescribed antihistamines included chlorpheniramine followed by cetirizine (19.27%) and loratadine (14.39%). Conclusion: Antihistamines were prescribed commonly in the outpatient setting mainly first-generation sedating antihistamines. It is recommended to increase the awareness of health- care providers about the efficacy and the side effects of antihistamines and to encourage them to use these agents wisely. Key words: Antihistamines, outpatient, prescribing, trends INTRODUCTION In addition, antihistamines have been classified as sedating antihistamines (first-generation antihistamines) and non- ntihistamines are used in the sedating antihistamines (second-generation antihistamines).[4] management of allergic conditions. Sedating antihistamines include chlorphenamine, clemastine, They are useful for treating the itching hydroxyzine, alimemazine, cyproheptadine, promethazine, A [1] and ketotifen.[4] Non-sedating antihistamines include that results from the release of histamine.
    [Show full text]
  • Your Child's Emergency Allergy Pack with Antihistamine
    Your Child’s Emergency Allergy Pack with Antihistamine Patient information Paediatric Department Watford General Hospital Hemel Hempstead Hospital If you need this leaflet in another language, large print, Braille or audio version, please call 01923 217 187 or email [email protected] Author Dr Ashley Reece Department Paediatrics Ratified Date / Review Date Feb 2021 / Feb 2024 Version Number / ID Number 40-1104-V1 Why does my child I need an Allergy Action Pack? An allergy action pan is a kit contianing evrything you need in case of an allergic reaction. Is my/ my child’s allergy severe? There is no such thing as a mild or severe allergy as reactions are always unpredicatble. However we do classify reactions as mild, moderate or severe. While it follows that a severe reaction makes the anxiety about the severity of the next reaction high, we cannot predict the severity of subsequent reactions. However there are some foods and some allergies which are assessed as having very low risk of a significant reaction. The way to manage your child with their allergy is to ensure you have the best possible safety net in case of an unforeseen reaction. Your doctor will give you a specific allergy plan (like the one to the right) which you should also give to your child’s school. Generally allergy is mananged by: You MUST avoid any foods which you know your child is allergic to. Avoidance Take care with labels and risk assess any new foods and when eating out in a restaurant or from a take-away.
    [Show full text]
  • AEC Traffic Light System
    Mental Health of Older Adults and Dementia Clinical Academic Group Anticholinergic Effect on Cognition (AEC) Scale Limited data so unable to score Drugs with AEC score of 0 Drugs with AEC Drugs with AEC score of 2 Drugs with AEC score of 3 score of 1 Alendronic Acid Ramipril Alprazolam Lovastatin Amiodarone Amantadine Alimemazine (trimeprazine) Allopurinol Rivaroxaban Amlodipine Lurasidone Aripiprazole Chlorphenamine Amitriptyline Anastrozole Rosuvastatin Amoxycillin Meloxicam Bromocriptine Desipramine Atropine Apixaban Spironolactone Aspirin Metoclopramide Carbamazepine Dicycloverine (dicyclomine) Benztropine Baclofen Tamoxifen Atenolol Metoprolol Citalopram Dimenhydrinate Chlorpromazine Bisoprolol Topiramate Atorvastatin Moclobemide Diazepam Diphenhydramine Clemastine Bumetanide Tizanidine Buproprion Morphine Domperidone Disopyramide Clomipramine Captopril Verapamil Cepahlexin Naproxen Fentanyl Levomepromazine (methotrimeprazine) Clozapine Carbimazole Zopiclone Cetirizine Omeprazole Fluoxetine Olanzapine Cyproheptadine Carvedilol Zotepine* Chlordiazepoxide Paracetamol Fluphenazine Paroxetine Dothiepin Chlortalidone Cimetidine Pantoprazole Hydroxyzine Pethidine Doxepin Clarithromycin Ciprofloxacin Pravastatin Iloperidone Pimozide Hyoscine hydrobromide Clonazepam Clopidogrel Propranolol Lithium Prochlorperazine Imipramine Codeine Darifenacin Rabeprazole Mirtazapine Promazine Lofepramine Colchicine Diclofenac Ranitidine Perphenazine Propantheline Nortriptyline Dabigatran Diltiazem Risperidone Prednisolone Quetiapine Orphenadrine Dexamethasone
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT (Invented name), film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Paracetamol..............................................................................................................................500.00 mg Chlorphenamine maleate..............................................................................................................4.00 mg For one film-coated tablet Excipients with known effect: Carmoisine (E122) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oblong purple film-coated tablet. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications This medicinal product is indicated for treatment, during the course of colds, rhinitis, rhinopharyngitis and flu-like conditions in adults and children aged over 15 years: of clear nasal discharge and watering of the eyes, of sneezing, of headaches and/or fever. 4.2 Posology and method of administration Posology Restricted to adults and children over the age of 15 years. Weight Dose per Administration Maximum daily dose (age) administration interval Adults and 1 tablet 4 hours 4 tablets children >50 kg i.e., i.e., (>15 years) 500 mg of paracetamol 2,000 mg of paracetamol 4 mg of chlorphenamine 16 mg of chlorphenamine Do not exceed the maximum posology of 4 tablets per 24 hours. Patients with renal failure In the event of renal failure and unless otherwise medically advised, it is recommended that the dose be reduced and that the minimum interval between the 2 doses be increased, based on the following table: 2 Creatinine Administration interval clearance ≥50 ml/min 4 hours 10–50 ml/min 6 hours <10 ml/min 8 hours The total dose of paracetamol should not exceed 3 g/day. Patients with hepatic failure In patients with active or compensated chronic hepatic disease, particularly those with hepatocellular insufficiency, chronic alcoholism, chronic malnutrition (low reserves of hepatic glutathione), and dehydration, the dose of paracetamol should not exceed 3 g/day.
    [Show full text]
  • Appendix 1 BNF Codes of Drugs Lists Used to Define Exposure Groups
    Appendix 1 BNF Codes of drugs lists used to define exposure groups. Anticholinergic antipsychotics d411. Chlorpromazine d412. Chlorpromazine d413. Chlorpromazine d414. Chlorpromazine d415. Chlorpromazine d41a. Chlorpromazine d41b. Chlorpromazine d41c. Chlorpromazine d41d. Chlorpromazine d4b1. Perphenazine d4e1. PROMAZINE d4ex. PROMAZINE d4g.. Thioridazine d4g1. Thioridazine d4g2. Thioridazine d4g3. Thioridazine d4g5. Thioridazine d4g7. Thioridazine d4gp. Thioridazine d4gt. Thioridazine d4gu. Thioridazine d4gv. Thioridazine d4gw. Thioridazine d4gz. Thioridazine d4h.. Trifluoperazine d4h1. Trifluoperazine d4h2. Trifluoperazine d4h3. Trifluoperazine d4h4. Trifluoperazine d4hs. Trifluoperazine d4ht. Trifluoperazine d4hu. Trifluoperazine d4hx. Trifluoperazine d4l2. CLOZAPINE d4r1. OLANZAPINE d4r3. OLANZAPINE d4r7. OLANZAPINE d4s1. QUETIAPINE d4s2. QUETIAPINE d4s3. QUETIAPINE d4s5. QUETIAPINE d4ss. QUETIAPINE d4sx. QUETIAPINE Tricyclic antidepressants d7... d71.. Amitriptyline d711. Amitriptyline d712. Amitriptyline d713. Amitriptyline d719. Amitriptyline d71a. Amitriptyline d71b. Amitriptyline d71c. Amitriptyline d71d. Amitriptyline d71e. Amitriptyline d71f. Amitriptyline d71u. Amitriptyline d71v. Amitriptyline d71w. Amitriptyline d71y. Amitriptyline d71z. Amitriptyline d73.. Clomipramine d731. Clomipramine d732. Clomipramine d733. Clomipramine d736. Clomipramine d73s. Clomipramine d73t. Clomipramine d73u. Clomipramine d73v. Clomipramine d73w. Clomipramine d73z. Clomipramine d75.. DOSULEPIN d751. DOSULEPIN d752. DOSULEPIN d755. DOSULEPIN d756.
    [Show full text]
  • PIL Pharmagrip Capsules HK
    Package leaflet: Information for the user pharmagrip capsules Paracetamol/Phenylephrine hydrochloride/Chlorphenamine maleate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse or if the fever persists for more than 3 days or the pain lasts for more than 5 days (2 days in the case of sore throat). What is in this leaflet: 1. What pharmagrip capsules is and what it is used for 2. What you need to know before you take pharmagrip capsules 3. How to take pharmagrip capsules 4. Possible side effects 5. How to store pharmagrip capsules 6. Contents of the pack and other information 1. What pharmagrip capsules is and what it is used for pharmagrip capsules is a combination of paracetamol (an analgesic that reduces pain and fever), chlorphenamine (an antihistamine that relieves nasal secretion) and phenylephrine (which acts reducing nasal congestion). This medicine is indicated for relief of the symptoms of cold or flu conditions associated with mild or moderate pain, fever and nasal congestion and secretion in adults and adolescents over 12 years of age.
    [Show full text]
  • West Essex CCG Anticholinergic Side-Effects and Prescribing Guidance
    Anticholinergic side-effects and prescribing guidance . Anticholinergic (antimuscarinic) medications: associated with increased risks of impaired cognition and falls in patients over the age of 65 years. Recent research also points to a link to mortality increasing with the number and potency of anticholinergic agents prescribed. Anticholinergic Syndrome: is a state of confusion with characteristic features related to dysfunction of the autonomic parasympathetic (cholinergic) nervous system. Symptoms classified into systemic and CNS manifestations: o Systemic (peripheral) symptoms: Blurred vision, photophobia, non-reactive mydriasis, loss of accommodation response, flushed and dry skin, dry mouth, tachycardia, hypertension and fever. Gastrointestinal and urinary motility are frequently reduced o CNS symptoms: Delirium, agitation, disorientation, and visual hallucinations. Ataxia, choreoathetosis, myoclonus and seizures may also occur without peripheral symptoms. Medication Issues: several commonly prescribed medications that may not be thought of as anticholinergic have significant anticholinergic effects, which when taken with known anticholinergic medication can increase the risk of adverse effects. Many medication groups e.g. antihistamines, tricyclic antidepressants, drugs for asthma and COPD, cold preparations, hyoscine have varying degrees of anticholinergic activity and have the potential to cause Anticholinergic Syndrome . Clinicians should be aware of the risk for chronic anticholinergic toxicity and the fact that not all the symptoms may manifest in patients and if they do suffer some symptoms they could be wrongly attributed to another diagnosis Evidence . A study of patients over 65 found that 20% of participants who scored four or more had died by the end of the two year study period compared with 7% of patients with a score of zero.
    [Show full text]
  • EMERGENCY TREATMENT of ANAPHYLACTIC REACTIONS Resuscitation Council (UK)
    Resuscitation Council (UK) Emergency treatment of anaphylactic reactions Guidelines for healthcare providers Working Group of the Resuscitation Council (UK) January 2008 Areas covered by Annotated with links to NICE guidance July 2012 NICE Clinical Guidance CG134 are Review Date: 2016 highlighted in the text with a pink sidebar, which is a web link to the NICE CG134 Published by the Resuscitation Council (UK) NICE guidance web page 5th Floor, Tavistock House North Tavistock Square London WC1H 9HR Tel: 020 7388 4678 Fax: 020 7383 0773 E-mail: [email protected] Website: www.resus.org.uk Registered charity no. 286360 Copyright Resuscitation Council (UK) No part of this publication may be reproduced without the written permission of the Resuscitation Council (UK). Resuscitation Council (UK) Members of the Working Group Jasmeet Soar – Co-chair Working Group, Vice Chair Resuscitation Council (UK) Richard Pumphrey – Co-chair Working Group, Royal College of Pathologists Andrew Cant – Royal College of Paediatrics and Child Health Sue Clarke – Anaphylaxis Campaign Allison Corbett – British National Formulary Peter Dawson – Royal College of Radiologists Pamela Ewan – British Society for Allergy and Clinical Immunology Bernard Foëx – College of Emergency Medicine David Gabbott – Executive Committee Member Resuscitation Council (UK) Matt Griffiths – Royal College of Nursing Judith Hall – Royal College of Anaesthetists Nigel Harper – Association of Anaesthetists of Great Britain & Ireland Fiona Jewkes – Royal College of General Practitioners,
    [Show full text]
  • Myasthenia Gravis Or Lambert-Eaton Myasthenia Syndrome – Medicines That May Affect Patients
    CLINICAL GUIDELINE Myasthenia Gravis or Lambert-Eaton Myasthenia Syndrome – Medicines that may affect patients A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty. If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient. Version Number: 1 Does this version include n/a changes to clinical advice: Date Approved: 11th July 2018 Date of Next Review: 30th July 2021 Lead Author: Lesley Murray Approval Group: Medicines Utilisation Subcommittee of ADTC Important Note: The Intranet version of this document is the only version that is maintained. Any printed copies should therefore be viewed as ‘Uncontrolled’ and as such, may not necessarily contain the latest updates and amendments. Information for healthcare professionals Medicines that may affect patients with Myasthenia Gravis or Lambert-Eaton Myasthenic Syndrome There are certain medicines that have been reported to worsen or induce myasthenia gravis (MG), often by increasing muscular weakness, and should be used with caution in patients with this condition. The list of medicines in table 1 has been compiled to assist prescribers in the decision making process when prescribing medicines for patients with myasthenia gravis. The medicines in this list have been classed according to those which should be: ▲ ▲Absolutely contraindicated ▲ Avoided Used with caution Probably safe with patient monitoring.
    [Show full text]
  • Committee for Veterinary Medicinal Products
    The European Agency for the Evaluation of Medicinal Products EMEA/MRL/513/98-FINAL February 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS CHLORPHENAMINE SUMMARY REPORT 1. Chlorphenamine (synonyms: chlorpheniramine, chlorprophenpyridamine, CAS No 113-92-8) is a racemic substance classified as an antihistaminic of the alkylamine group. Chlorphenamine is used in cattle, sheep, goats, pigs and horses at doses of 0.4 to 0.5 mg/kg bw/day for 3 to 5 days, intramuscularly in combination with antibiotics and occasionally with corticosteroids for treatment of respiratory diseases. Chlorphenamine is also used in humans at oral doses of 2 mg to 24 mg/person/day and intramuscularly, subcutaneously or intravenously up to 40 mg/person/day. 2. Chlorphenamine maleate is described as a histamine H1-receptor antagonist. This drug also possesses, in different degrees, a variety of other actions, particularly within the central nervous system (transient hypotension or stimulation) like other substances of the pharmacodynamic group. The two isomers of chlorphenamine differ in antihistaminic potency: the dextro-form is 100 times more active than the levo-isomer and 2.5 times more than the racemic form. From the in vivo data provided, it was shown that a single oral administration of 0.128 mg/kg bw of chlorphenamine protected 50% of the guinea pigs in a test for antihistaminic activity. No pharmacological NOEL could be derived from this study. In another test for anaphylatic shock protection in guinea pigs a single oral dose of 0.51 mg/kg protected 38% of the animals and 0.11 mg/kg could be retained as a LOEL for this study.
    [Show full text]